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A small animal model that reproduces human immunodeficiency virus type 1 (HIV-1) pathogenesis may
allow modeling of new therapeutic strategies in ways not approachable in mononuclear cell culture. We find
that, as in humans, combination antiretroviral therapy (ART) in humanized (hu-) Rag2/c
/ mice allows
suppression of viremia below the limits of detection and recovery of CD4 cells, while interruption of ART
results in viral rebound and renewed loss of CD4 T cells. Failure of ART in infected mice is associated with
the appearance of drug resistance mutations. The hu-Rag2/c
/ mouse may therefore facilitate testing of
novel approaches to HIV replication and persistence.
Combination antiretroviral therapy (ART) is best tested in a
complete biological system but is difficult to test in nonhuman
primates (NHPs) (1). NHPs infected with a chimeric simian-
human immunodeficiency virus (SHIV) encoding human im-
munodeficiency virus type 1 (HIV-1) reverse transcriptase
(RT-SHIV) can be used to test reverse transcriptase inhibitors;
however, NHP resources are limited (2, 18). BLT (bone mar-
row liver thymic) mice have been successfully used to model
antiretroviral preexposure prophylaxis, but have not yet been
used to model ART (7).
Humanized (hu-) Rag2/c
/ mice, reconstituted with
human CD34 hematopoietic stem cells (HSCs), display en-
graftment of T, B, myeloid, and NK cells in both central and
peripheral lymphoid organs (3, 22, 23). Substantial plasma
viremia and systemic depletion of human CD4 T cells follow
infection with CCR5- or CXCR4-tropic HIV (4, 23).
The nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) tenofovir (TFV) disoproxil fumarate (TDF) and
emtricitabine (FTC) have long elimination half-lives and are
widely used as part of daily ART (10). The strand transfer
inhibitor (InSTI) raltegravir is being studied for use in initial
therapy for HIV with TDF/FTC (17), and InSTI L-870812 is
potent in the SHIV-infected macaque (13). Due to the diffi-
culty of reliable long-term dosing of protease inhibitors and
nonnucleoside RTIs in mice, we chose to study a dual NRTI-
InSTI regimen in hu-Rag2/c
/ mice.
hu-Rag2/c
/ mice suffered depletion of hu-CD4 T
cells following HIV-1 infection, a prompt decline in plasma
viremia after the initiation of ART, and recovery of hu-CD4
T cells following therapy. In some treated mice, viremia re-
bounded after initial suppression, in association with RTI and
InSTI resistance mutations. Recapitulating ART in humans,
hu-Rag2/c
/ mice are a promising model for testing ART
and novel therapeutic strategies.
ART dosing and PK studies in Rag2/c
/ mice. Rag2/
c
/ mice were dosed with single intraperitoneal injection of
L-870812, FTC, and TFV at 20, 60, and 50 mg/kg body weight,
respectively. Doses were based on previous studies in mice and
NHPs (13, 18, 20). The concentrations of drugs were measured
simultaneously using a multiplex high-performance liquid
chromatography method with UV detection (19). Serum was
subjected to solid-phase extraction using BOND ELUT C18
columns. Intestinal tissue (IT) samples were subjected to solid-
phase extraction after homogenization. Analytes were sepa-
rated using an Atlantis dC18 analytical column (Waters Corp.,
Milford, MA) and a gradient elution. Calibration curves for
both matrices ranged from 5 to 1,000 ng/ml for TFV and
L-870812 and from 10 to 1,000 ng/ml for FTC. Interday and
intraday coefficients of variation across the range of concen-
trations were less than 13%.
Table 1 shows the pharmacokinetic (PK) parameters of
each antiretroviral in blood plasma and IT over a 24-h
* Corresponding authors. Mailing address for S. K Choudhary: Uni-
versity of North Carolina at Chapel Hill, 3206 Michael Hooker Re-
search Ctr., CB#7435, Chapel Hill, NC 27599-7435. Phone: (919)
966-6389. Fax: (919) 966-0584. E-mail: schoudha@med.unc.edu.
Mailing address for D. M. Margolis: University of North Carolina at
Chapel Hill, 3302 Michael Hooker Research Ctr., CB#7435, Chapel
Hill, NC 27599-7435. Phone: (919) 966-6388. Fax: (919) 966-0584.
E-mail: dmargo@med.unc.edu.
† Supplemental material for this article may be found at http://jvi
.asm.org/.
 Published ahead of print on 3 June 2009.
8254
period in Rag2/c
/ mice and their comparison to hu-
man plasma (6). The PK of TFV, FTC, and L-870812 were
evaluated by noncompartmental methods using WinNonlin
(5.1; Pharsight, Mountain View, CA). The terminal elimi-
nation rate constant (z) was estimated by linear regression
of the terminal portion of the log-transformed concentra-
tion versus time curve using at least the last three data
points in the terminal elimination phase. The terminal half-
life (t1/2) was calculated as ln(2)/z. The maximum observed
concentration (Cmax) was obtained directly from the con-
centration-time profile. The area under the curve (AUC)
from time 0 to the last measured concentration at 24 h (C24),
AUC0-24, was determined using the trapezoidal rule with
linear-up/log-down interpolation.
Serum concentrations of TFV and FTC dosed intraperi-
toneally in mice were similar to C24s achieved in humans
when dosed orally (Table 1 and Fig. 1). The median t1/2s of
TFV and FTC in IT were 10 h and 17 h, respectively, and
were two- to fourfold higher than in serum. This indicates a
continued presence of drug in cells, despite a decline in
plasma drug concentration. In contrast to human metabo-
lism, enterohepatic recirculation was observed for all three
drugs between 6 and 12 h. Although enterohepatic recircu-
lation can alter the PK of drugs by increasing exposure,
reducing clearance, and extending half-life, this property
allows drug dosing in mice at a frequency used in humans to
obtain similar concentrations at C24.
The serum concentration of L-870812 at 12 h was well above
the 95% inhibitory concentration (250 to 350 nM), but de-
clined to 21 nM at 24 h (13). InSTI, however, acts in a nonre-
versible manner, and so antiviral effect may persist after
plasma concentrations decline (11). Total concentrations of
parent drugs measured in IT were also sufficient to suppress
viremia, suggesting that once-daily antiviral dosing could be




/ mice are engrafted with long-lived mem-
ory CD4 T cells. hu-Rag2/c
/ mice were created by
transplanting human fetal liver-derived CD34 cells (0.5  106
to 1  106) into the livers of newborn conditioned Rag/c
/
mice as previously described (5, 22, 23), with modifications.
Briefly, CD34 HSC were cultured overnight in RPMI 1640
medium containing interleukin-3 (IL-3), IL-6, and stem cell
factor (1, 1, and 2 g/ml, respectively) prior to injection. We
found stable engraftment of hu-CD45 T cells in peripheral
blood (PB) and lymphoid tissue (Fig. 2A). More than 50% of
the hu-CD4 T cells in PB, lymph node (LN), spleen, and IT
were CD45RO memory cells, a site of persistent HIV-1 in-
TABLE 1. Plasma and tissue PK parameters for TFV, FTC, and L-870812a
Sample type and drug Cmaxb C24b AUC0–24c t1/2 (h)
Mouse plasma
TFV 3,660 (262–9,936) 38 (1–13) 12,122 (7,631–85,570) 5 (2–8)
FTC 18,641 (670–22,784) 46 (16–69) 49,514 (27,055–149,002) 4 (3–5)
L-870812 4,996 (330–13,720) 8 (0.5–10) 15,095 (2,878–65,128) 3 (2–4)
Mouse IT
TFV 39 (7–88) 4 (2–31) 352 (87–513) 10 (7–12)
FTC 31 (8–51) 5 (1–15) 175 (54–191) 17 (4–36)
L-870812 31 (8–67) 0.4 (0.1–2) 87 (48–236) 4 (2–8)
Human plasma
TFV 292 53 2,650 15
FTC 1,650 71 11,000 10
a Median values are presented, with ranges in parentheses. Mouse PK parameters were compared with human data as described in reference 5.
b Values are ng/ml for mouse and human plasma and ng/mg for IT.
c Values are h  ng/ml for mouse and human plasma and h  ng/mg for IT.
FIG. 1. Pharmacokinetics of ART in Rag2/c
/ mice. Mice were dosed with FTC, TFV, and L-870812 (L-812) at 60, 50 and 20 mg/kg body
weight by single intraperitoneal injection. Serum and gastrointestinal tissue samples from ileum and rectum were collected and frozen at 80°C
until analysis. As the PK profiles were similar for ileum and rectal regions of IT, data were combined. The data shown are the mean
concentration  standard error of the single-dose PK profile of FTC, TFV, and L-870812 over a 24-h period in serum (A) and IT (B) of mice after
combined intraperitoneal injection. n  3 for serum, and n  6 for tissue.
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fection. The majority of CD45RO CD4 T cells residing in
the spleen and LN lacked the activation markers CD25 (Fig.
2B), CD69, and HLA-DR (data not shown). In contrast,
CD45RO CD4 cells in blood and IT expressed CD25 but
lacked HLA-DR (data now shown), indicating partial activa-
tion status. We recovered human cells from IT by collagenase
D digestion (21) of the entire intestine, including ileum and
rectum, followed by Ficoll-Paque enrichment of human lym-
phocytes. We observed more than 5% hu-CD45 cells in two
of six mice, which was infrequent compared to that in BLT
mice (21). Our results are consistent with the findings of
Berges et al. (4), who similarly reconstitute mice with cytokine-
treated CD34 HSCs, but in contrast to those of Hofer et al.
(14).
We noted that even hu-Rag2/c
/ mice with poor circu-
lating human cell engraftment (1 to 5%) had higher engraft-
ment in lymphoid organs; 75% of cells in thymus and LN were
hu-CD45. Engrafted hu-CD4 T cells expressed both CCR5
and CXCR4 coreceptors (Fig. 2C), and therefore could be
infected by either CCR5- or CXCR4-tropic virus. Major lym-
phoid organs also contained CD11b myeloid/NK cells
(Fig. 2D) and CD14 macrophages (data not shown). hu-
Rag2/c
/ mice therefore possess the critical cells neces-
sary to model HIV-1 infection and ART.
Novel ART in HIV-1-infected hu-Rag2/c
/ mice allows
viral suppression and recovery of hu-CD4 T cells. We in-
fected six mice intravenously with CCR5-tropic HIV-1 JR-CSF
and monitored plasma viremia and hu-CD4 T-cell percentage
over a 4-month period (Fig. 2E). Plasma viremia was assayed
using the Abbott RealTime reverse transcription (RT)-PCR
automated m2000 system (Abbott, Des Plaines, IL). All mice
became infected, and a decline in hu-CD4 T cells was ob-
served following peak viremia. Due to high levels of viremia
and rapid and profound hu-CD4 depletion seen in preliminary
studies (see Fig. S1 in the supplemental material), ART was
initiated at 8 days postinfection in all mice except M4, in which
ART was initiated at 18 days postinfection. Infected mice were
treated daily by intraperitoneal injection. Mice that received
prompt ART had a decline in plasma viremia of 0.6 to 1.5 log
in 10 days of treatment. In contrast, viral load increased in M4,
in which ART was delayed and viral suppression lagged by
the approximately the same length of time. Untreated mice
maintained high viral loads (see Fig S1 in the supplemental
material).
Suppression of viremia following ART allowed recovery of
hu-CD4 T cells in the PB. Interestingly, we observed that
CD4 T-cell rebound occurred in M1 and M4 even when
viremia was only partially suppressed. We noted an increase in
percentage of hu-CD4 cells relative to hu-CD45 cells (see
Fig. S2 in the supplemental material), which indicates that in
response to CD4 depletion, a selective proliferation of T cells
occurred. An increase in CD4 T-cell number despite an in-
crease in viremia for a shorter time period was also observed by
another group in this model (3, 5). It is likely that partial
suppression of viremia by ART enabled the response of T-cell
homeostasis mechanisms.
Continuation of ART resulted in viral suppression below the
limit of detection at 7 to 9 weeks of treatment in three mice
(M1, M2, and M4). We observed a typical initial rapid decline
in plasma viremia after the start of ART followed by a gradual
decline. Discontinuation of ART after suppression of viremia
in M1 and M2 resulted in viral rebound and renewed loss of
hu-CD4 T cells. Mice M3 and M6 also showed initial viral
suppression and increases in circulating hu-CD4 cells; how-
ever, evaluation was incomplete due to the death of the mice.
Incidental mortality is sometimes seen in this humanized
mouse model, and drug toxicity is not likely to be causal: longer
periods of ART (3.5 months) were well tolerated in other
animals.
In M5, following an initial decline, viremia increased rapidly.
M4 exhibited a delayed response to ART. We sequenced the
viral polymerase (pol) gene to seek evidence of drug resistance
mutations. Amplicons were generated from limiting dilution
PCR using the ABI BigDye Terminator system. We detected
drug resistance mutations associated with NRTIs (K65R) (16)
and InSTI (M154I) (12) in M4 after rebound and M5 at failure
(Table 2). M5 exhibited another mutation associated with
raltegravir resistance (E92Q) (15). The significance of muta-
tion in the conserved DD(35)E motif (E152I) of integrase in
relation to drug resistance is not known (8, 9).
In summary, combination ART in HIV-1-infected hu-
Rag2/c
/ mice recapitulates many aspects of ART in hu-
mans. Suppression of viremia, CD4 T-cell maintenance and
recovery, viral persistence, and the emergence of drug-resis-
tant virus are observed in this model. Model systems such as
this one may allow the testing of novel approaches to the
FIG. 2. hu-CD4 T-cell reconstitution, infection, and novel antiretroviral therapy in hu-Rag2/c
/ mice. (A) T-cell reconstitution at 20
weeks postengraftment. Live cells were defined based on their forward and side scatter and single cells based on forward scatter height and area.
Single, live cells were subsequently gated on the hu-CD45/mouse CD45 and hu-CD3 population. (B) Memory hu-CD4 T cells reconstitute in
blood and tissue. Human T cells gated on the CD4 population (circled) were analyzed for memory marker CD45RO and activation marker CD25.
PBMC, peripheral blood mononuclear cells. (C) hu-CD4 T-cell expression of CCR5 and CXCR4. (D) hu-CD11b cells are detected in several
lymphoid tissues. (E) Suppression of plasma viremia and recovery of hu-CD4 T cells in individual hu-Rag2/c
/ mice. Animals were infected
with JRCSF (25 ng p24/mouse) and treated with L-870812, TFV, and FTC at 20, 50, and 60 mg/kg/daily, respectively. Blue lines and squares show
plasma viremia, while green lines and triangles show CD4 percentages, both drawn on a logarithmic scale. The percentage of hu-CD4 T cells
represents the percentage of this cell population in total peripheral blood mononuclear cells obtained from mouse blood. The percentage of
hu-CD4 T cells  % hu-CD45/mouse CD45 cells  (% CD3 cells gated on hu-CD45 cells/100)  (% CD4 cells gated on hu-CD45
CD3/100). Due to the small available volume of mouse plasma, dilution is required, and so the limit of assay detection of viral RNA is 	500 copies
(Cps)/ml. Shading indicates time prior to infection (green), following infection (purple), after initiation of ART (yellow), and following discon-
tinuation of ART (gray). TFV- and L-870812-related mutations were detected in plasma of M4 and M5 upon failure of therapy or rebound.
Experiments terminated by death of the mouse are indicated by asterisks.
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treatment of HIV infection beyond standard ART, such as
gene therapy or eradication approaches.
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